Related Experiment Videos
Abnormal mRNA Expression Levels of Telomere-Binding Proteins Represent Biomarkers in Myelodysplastic Syndromes: A
Baoshan Liu, Rongdi Yan, Jie Zhang
1Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Department of Hematology, Jinan, China.
Objective:
As evidence was shown that abnormal shortening of telomeres begins to accumulate in myelodysplastic syndrome (MDS) patients, this study was conducted to determine the relationship between the mRNA expression levels of telomere-binding proteins (TRF1/TRF2/TIN2/TPP1/POT1/RAP1) and the risk level in MDS.
Materials And Methods:
There were 40 patients with MDS and 40 normal controls in this study. Methods including telomere content assays and quantitative reverse transcription-polymerase chain reaction were used to examine the mRNA levels of TRF1/TRF2/TIN2/TPP1/POT1/RAP1 in patients with MDS.
Results:
Compared to the normal group used as a control, the mRNA expression levels of RAP1/POT1/TPP1 of the patients with MDS were decreased, whereas their levels of TRF1/TRF2 and TIN2 were increased. A positive correlation was found between the TRF1, TRF2, and TIN2 mRNA expression levels and the risk level of the International Prognostic Scoring System (IPSS) and the World Health Organization Prognostic Scoring System (WPSS) criteria; however, a negative correlation was found between RAP1/POT1/TPP1 mRNA expression levels and the risk levels of IPSS and WPSS criteria.
Conclusion:
Because the reduction of TRF1/TRF2/TIN2 mRNA expression and the increase of RAP1/POT1/TPP1 mRNA expression are closely related to the risk levels of the IPSS and WPSS criteria in MDS, it is thought that these telomere-binding proteins could lead to abnormal telomere length and function, which cause chromosomal abnormalities in MDS. With this evidence, we suggest that those proteins' mRNA expressions could be used as biomarkers for the assessment of the risk degree of MDS patients.
Insights
This study found that altered mRNA expression of telomere-binding proteins correlates with myelodysplastic syndrome (MDS) risk. These protein levels may serve as biomarkers for assessing MDS risk and progression.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Myelodysplastic syndromes (MDS) are characterized by abnormal hematopoiesis and telomere shortening.
- Telomere-binding proteins play crucial roles in maintaining telomere stability and function.
Purpose of the Study:
- To investigate the relationship between mRNA expression levels of key telomere-binding proteins (TRF1, TRF2, TIN2, TPP1, POT1, RAP1) and risk stratification in MDS patients.
Main Methods:
- Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was employed to measure mRNA levels.
- Telomere content assays were also performed.
- MDS patients (n=40) and healthy controls (n=40) were included.
Main Results:
- MDS patients exhibited decreased mRNA expression of RAP1, POT1, and TPP1, and increased expression of TRF1, TRF2, and TIN2 compared to controls.
- TRF1, TRF2, and TIN2 mRNA levels positively correlated with MDS risk scores (IPSS, WPSS).
- RAP1, POT1, and TPP1 mRNA levels negatively correlated with MDS risk scores (IPSS, WPSS).
Conclusions:
- Aberrant expression of telomere-binding proteins is linked to MDS risk.
- These proteins may contribute to abnormal telomere length and chromosomal abnormalities in MDS.
- mRNA expression levels of these proteins show potential as biomarkers for MDS risk assessment.